stockrowBillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) Free cash flow margin
BillionToOne, Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 7.76%, up 2.6 percentage points from fiscal 2025 (5.15%). That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 5.15% | 35.81 |
| FY2024 | −30.7% | 52.77 |
| FY2023 | −83.4% | — |
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| VCYT Veracyte, Inc. compare | 27.8% |
| QGEN QIAGEN N.V. compare | 21.0% |
| CDNA CareDx, Inc. compare | 12.0% |
| SHC Sotera Health Company compare | 11.0% |
| BLLN BillionToOne, Inc. | 7.76% |
| RDNT RadNet, Inc. compare | 3.28% |
| ADPT Adaptive Biotechnologies Corporation compare | −2.96% |
| NEO NeoGenomics, Inc. compare | −3.37% |
| GRAL GRAIL, Inc. compare | −187.3% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement